Understanding how certain immune cells affect T cell function in kidney cancer treatment
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11051217
This study is looking at how certain immune cells called tumor-associated macrophages affect kidney cancer and how they might change the way your body responds to treatment, with the goal of finding better ways to help patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11051217 on ClinicalTrials.gov |
What this research studies
This research investigates the role of tumor-associated macrophages (TAMs) in clear cell renal cell carcinoma (ccRCC), a common and aggressive form of kidney cancer. The study aims to identify specific subpopulations of TAMs that influence T cell behavior and therapeutic responses. By analyzing immune cell populations in different patient tumor samples, the researchers hope to uncover mechanisms of treatment resistance and develop strategies to enhance the effectiveness of existing therapies. Patients may benefit from insights that could lead to more targeted and effective treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced clear cell renal cell carcinoma who are undergoing or have undergone treatment.
Not a fit: Patients with early-stage kidney cancer or those not diagnosed with clear cell renal cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with advanced kidney cancer, potentially overcoming resistance to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting immune cells to enhance cancer treatment, indicating that this approach may be viable.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAKIMI, ABRAHAM ARI — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: HAKIMI, ABRAHAM ARI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced disease